HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting Tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engagers (BiTE) related to manufacturability, safety profile, and ability to treat a wide spectrum of solid tumors GlobeNewswire November 07, 2025 MIRAMAR, Fla., Nov. […]

Boralex announces its third quarter results and commissioning of large-scale projects in Canada GlobeNewswire November 07, 2025 MONTREAL, Nov. 07, 2025 (GLOBE NEWSWIRE) — Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the third quarter of 2025. Highlights Financial results EBITDA(A)1, operating income and net earnings decline in

RIMAN, the premium K-Beauty and wellness brand, is making significant strides on the global stage with two landmark events that underscore its rising influence in international markets. https://mma.prnewswire.com/media/2816976/UK.jpg RIMAN officially made its European debutwith the RIMAN UK Grand Openingat Novotel London Weston October 19, 2025, attracting over 1,200 attendees. Ahead of the launch, RIMAN opened

Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting(R) 2025 GlobeNewswire November 07, 2025 Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compensated cirrhosis (F4c)

Quantum Biopharma Reports Strong Third Quarter Results Maintaining 'No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio Quarter Shows Company's Continued Strong Financial Position and Momentum with its MS Clinical Trials and unbuzzd(TM) Recreational Beverage and Alcohol Metabolizer GlobeNewswire November 07, 2025 TORONTO, Nov. 07, 2025

RYTHM, Inc. Reports Third Quarter 2025 Results GlobeNewswire November 07, 2025 ROLLING MEADOWS, Ill., Nov. 07, 2025 (GLOBE NEWSWIRE) — RYTHM, Inc. (Nasdaq: RYM) (“RYTHM” or the “Company”) (formerly known as Agrify Corporation), which delivers well-being to consumers through its portfolio of iconic licensed brands and hemp-derived THC products including Senorita THC Margaritas and RYTHM,

Hain Celestial Reports Fiscal First Quarter 2026 Financial Results GlobeNewswire November 07, 2025 HOBOKEN, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) — The Hain Celestial Group, Inc. (Nasdaq: HAIN), a leading global health and wellness company whose purpose is to inspire healthier living through better-for-you brands, today reported financial results for its fiscal first quarter ended

Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025 Studies spanning cardiovascular, aging, and cancer biology highlight how Seer's Proteograph(R) platform is enabling discovery at population scale GlobeNewswire November 07, 2025 REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), the pioneer and

Onex Reports Third Quarter 2025 Results GlobeNewswire November 07, 2025 All amounts in U.S. dollars unless otherwise stated TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today announced its financial results for the third quarter ended September 30, 2025. “Onex' third quarter results reflect ongoing progress across the business,” said Bobby Le

Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire November 07, 2025 — New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 — — Nominated PM647 as development candidate for Alpha-1